Soligenix, Inc. (SNGX)
SNGX Stock Price Chart
Explore Soligenix, Inc. interactive price chart. Choose custom timeframes to analyze SNGX price movements and trends.
SNGX Company Profile
Discover essential business fundamentals and corporate details for Soligenix, Inc. (SNGX) to support your stock research and investment decisions.
Sector
Healthcare
Industry
Biotechnology
IPO Date
4 Apr 1994
Employees
14.00
Website
https://www.soligenix.comCEO
Christopher J. Schaber
Description
Soligenix, Inc., a biopharmaceutical firm in its advanced development stages, concentrates on bringing innovative products to market within the United States, specifically targeting rare illnesses. The company's operations are divided into two main divisions: Specialized BioTherapeutics and Public Health Solutions. Within the Specialized BioTherapeutics division, Soligenix is advancing SGX301 (marketed as HyBryte), a novel photodynamic treatment that has successfully completed its Phase III clinical trials for managing cutaneous T-cell lymphoma. This segment also includes SGX942, an innate defense regulator technology currently undergoing Phase III trials for various inflammatory conditions, notably oral mucositis in patients with head and neck cancer. Additionally, this division is pursuing proprietary oral formulations of beclomethasone 17,21-dipropionate designed to prevent or treat severe inflammatory gastrointestinal disorders, such as SGX203 for pediatric Crohn's disease. Another candidate, SGX302, is currently in Phase I/II clinical development for addressing mild-to-moderate psoriasis. The Public Health Solutions segment is dedicated to developing several critical assets. These include RiVax, a vaccine candidate against ricin toxin, which has successfully completed Phase Ia and Ib clinical evaluations; SGX943, a therapeutic agent in pre-clinical studies aimed at combating antibiotic-resistant and emerging infectious diseases; ThermoVax, an early-stage technology focused on enhancing vaccine thermostability; and CiVax, a pre-clinical vaccine candidate intended for COVID-19 prevention. Soligenix, Inc. was originally established as DOR BioPharma, Inc. before adopting its current name in 2009. Founded in 1987, the company maintains its corporate headquarters in Princeton, New Jersey.
SNGX Financial Timeline
Browse a chronological timeline of Soligenix, Inc. corporate events including earnings releases, dividend announcements, and stock splits.
Upcoming earnings on 13 Aug 2026
EPS estimate is -$0.16.
Earnings released on 8 May 2026
EPS came in at -$0.28 surpassing the estimated -$0.30 by +6.67%.
Earnings released on 3 Apr 2026
EPS came in at $0.32 surpassing the estimated -$0.27 by +218.52%.
Earnings released on 7 Nov 2025
EPS came in at -$0.58 surpassing the estimated -$0.63 by +7.94%.
Earnings released on 14 Aug 2025
EPS came in at -$0.82 falling short of the estimated -$0.79 by -3.80%.
Earnings released on 9 May 2025
EPS came in at -$1.06 falling short of the estimated -$0.67 by -58.21%.
Earnings released on 21 Mar 2025
EPS came in at -$1.14 falling short of the estimated -$0.95 by -20.00%, while revenue for the quarter reached $6.35k , missing expectations by -96.82%.
Earnings released on 8 Nov 2024
EPS came in at -$0.78 surpassing the estimated -$1.09 by +28.44%.
Earnings released on 9 Aug 2024
EPS came in at -$1.31 surpassing the estimated -$2.11 by +37.91%, while revenue for the quarter reached $2.34k , missing expectations by -98.83%.
Stock split effective on 6 Jun 2024
Shares were split 1 : 16 , changing the number of shares outstanding and the price per share accordingly.
Earnings released on 10 May 2024
EPS came in at -$2.88 surpassing the estimated -$3.20 by +10.00%, while revenue for the quarter reached $117.03k , missing expectations by -41.49%.
Earnings released on 15 Mar 2024
EPS came in at -$2.56 surpassing the estimated -$3.04 by +15.79%, while revenue for the quarter reached $244.81k , beating expectations by +22.41%.
Earnings released on 13 Nov 2023
EPS came in at -$2.56 surpassing the estimated -$7.04 by +63.64%, while revenue for the quarter reached $130.44k , missing expectations by -34.78%.
Earnings released on 21 Aug 2023
EPS came in at -$2.72 surpassing the estimated -$7.84 by +65.31%, while revenue for the quarter reached $206.93k , beating expectations by +3.46%.
Earnings released on 15 May 2023
EPS came in at -$5.76 surpassing the estimated -$20.00 by +71.20%, while revenue for the quarter reached $257.18k , beating expectations by +28.59%.
Earnings released on 31 Mar 2023
EPS came in at -$4.58 falling short of the estimated -$1.12 by -308.93%, while revenue for the quarter reached $366.07k , beating expectations by +83.03%.
Stock split effective on 10 Feb 2023
Shares were split 1 : 15 , changing the number of shares outstanding and the price per share accordingly.
Earnings released on 10 Nov 2022
EPS came in at -$19.19 matching the estimated -$19.19, while revenue for the quarter reached $166.14k , missing expectations by -16.93%.
Earnings released on 12 Aug 2022
EPS came in at -$14.39 surpassing the estimated -$16.79 by +14.29%, while revenue for the quarter reached $228.64k , beating expectations by +14.32%.
Earnings released on 13 May 2022
EPS came in at -$23.99 falling short of the estimated -$14.39 by -66.71%, while revenue for the quarter reached $188.06k , beating expectations by +88.06%.
Earnings released on 29 Mar 2022
EPS came in at -$26.39 falling short of the estimated -$19.19 by -37.52%, while revenue for the quarter reached $275.65k , beating expectations by +37.83%.
Earnings released on 12 Nov 2021
EPS came in at -$21.59 surpassing the estimated -$31.18 by +30.76%, while revenue for the quarter reached $186.20k , missing expectations by -55.67%.
Earnings released on 13 Aug 2021
EPS came in at -$11.99 surpassing the estimated -$26.39 by +54.57%, while revenue for the quarter reached $214.82k , missing expectations by -60.22%.
SNGX Stock Performance
Access detailed SNGX performance analysis with candlestick charts, real‑time intraday data and historical financial metrics for comprehensive insights.
Explore Related Stocks
Compare companies within the same sector by viewing performance, key financials, and market trends. Select a symbol to access the full profile.
